Ai-enhanced DNA origami nanoparticle vaccine for IBV
DoriVac, an AI-enhanced DNA origami nanoparticle platform, offers a novel, thermostable vaccine for avian infectious bronchitis virus (IBV) in poultry. It combines AI-driven antigen prediction with DNA nanostructures to improve immune responses, addressing limitations of current vaccines.
Overview
The AI-enhanced DNA Origami nanoparticle vaccine, DoriVac, provides a groundbreaking solution for controlling avian infectious bronchitis virus (IBV) in poultry. This innovative vaccine leverages the DoriVac platform, which integrates programmable DNA origami nanoparticles with AI-driven antigen prediction to identify conserved and immunogenic targets from circulating IBV strains. This approach ensures a rationally designed, thermostable vaccine that enhances both humoral and cellular immune responses, overcoming the limitations of existing poultry vaccines.
Technical specifications
- Programmable DNA Origami Nanoparticles: Utilize nanostructured DNA frameworks for co-delivery of antigens and adjuvants in optimized configurations.
- AI-driven Antigen Prediction: Employs AI tools to predict immunogenic epitopes, ensuring broad coverage against diverse IBV strains.
- Thermostability and Scalability: Designed for high manufacturability, the platform ensures the production of a stable vaccine suitable for widespread use in poultry.
- Modular and Adaptable: The DoriVac platform is highly adaptable, opening possibilities for vaccine development across various veterinary applications.
Technology readiness level
Currently at Technology Readiness Level 4, DoriVac has demonstrated promising results in preclinical murine models. The next steps involve comprehensive validation in both in vitro and in vivo settings with healthy mice and optimized poultry models to assess immune responses and vaccine efficacy. These efforts aim to establish benchmarks for disease severity and therapeutic efficacy, paving the way for future vaccine assets in veterinary medicine.
About DoriNano, Inc.
DoriNano, Inc. is a biotechnology company focused on developing advanced nanomedicine platforms based on DNA origami technology. The company utilizes DNA as a structural material to engineer 3D delivery vehicles that provide precise, nanoscale control over the spacing and stoichiometry of therapeutic payloads. This approach allows for the programmable design of drug delivery systems, offering benefits such as enhanced stability, versatile cargo conjugation, high drug loading capacity, and reduced immunogenicity compared to traditional nanoparticle delivery methods. The core technology originated from research conducted at the Dana-Farber Cancer Institute and the Wyss Institute at Harvard University.
By enabling the precise placement of drug combinations, DoriNano aims to significantly improve treatment efficacy for serious diseases, including cancer. Preclinical studies have demonstrated that the specific nanoscale arrangement of biological payloads can increase receptor binding affinity and downstream biological activity, potentially reducing required dosages by 10-100 fold. The company is initially applying this platform to the development of cancer vaccines, such as its DoriVac program for head and neck squamous cell carcinoma, and has entered into research collaborations to further expand the reach of its therapeutic delivery innovations.
delivered to your inbox.